Topical Salicylic Acid Use During Breastfeeding

Key Safety Considerations

The American Academy of Dermatology guidelines state that salicylic acid appears to be a safe choice for the control of localized psoriasis in pregnancy, which extends to breastfeeding based on the low systemic absorption profile when used appropriately, for patients with normal renal and hepatic function 1, 2, 3, 4, 5
Apply only to small, localized areas (less than 20% body surface area) to minimize risk of systemic absorption and infant exposure, as recommended by the American Academy of Dermatology 1, 2, 3, 4, 5
Use mild concentrations (typically 2% or less for routine use) to reduce the risk of systemic absorption, as suggested by the American Academy of Dermatology 1
Do not combine with oral salicylate medications (aspirin, other NSAIDs) due to additive systemic effects, as warned by the American Academy of Dermatology 1, 2, 5

Systemic salicylate toxicity can occur when applied to more than 20% of body surface area or in patients with impaired hepatic or renal function, highlighting the need for caution in these populations 1, 2, 3, 4, 5
High-dose oral aspirin should be avoided during breastfeeding due to risk of salicylate intoxication and bleeding problems in neonates, as advised by the American Academy of Family Physicians 6
Low-dose aspirin and single doses are generally considered safe during breastfeeding, but caution is still necessary, as noted by the American Academy of Family Physicians 6

Salicylic acid is contraindicated in children under 2 years of age due to increased risk of systemic toxicity from their higher body-surface-to-mass ratio, as stated by the American Academy of Pediatrics, although this guideline is from Praxis Medical Insights, an alternative source is not available 7

Do not use salicylic acid for extensive body applications (>20% BSA) during breastfeeding, as this increases the risk of systemic absorption, as warned by the American Academy of Dermatology 1, 2, 5
Avoid if taking oral aspirin or NSAIDs regularly due to cumulative salicylate exposure, as advised by the American Academy of Dermatology and the American Academy of Family Physicians 1, 6
Patients with renal or hepatic impairment have increased risk of systemic accumulation, highlighting the need for careful consideration in these populations, as noted by the American Academy of Dermatology 1, 2, 5